Why Dr. Ken Sharlin Believes Most Neurological Diseases Are Reversible
March 18, 2026
In this episode of Power to the Patients, host Brandon Li sits down with Dr. Ken Sharlin, neurologist, researcher, and clinical trial investigator, to explore how precision medicine, functional neurology, and emerging technologies are redefining what’s possible in neurodegenerative disease care. Dr. Sharlin challenges the traditional disease-centered model and shares why restoring biological balance - rather than simply managing symptoms, may unlock new pathways for prevention, reversal, and personalized treatment in conditions like MS, Alzheimer’s, and Parkinson’s.
In this episode of Power to the Patients, Brandon Li speaks with Dr. Ken Sharlin, a neurologist and principal investigator with decades of experience across clinical practice, functional medicine, and clinical research. Dr. Sharlin shares his journey from traditional academic neurology to a systems-based, precision medicine approach that focuses on restoring homeostasis rather than treating diagnoses in isolation.
The conversation explores why lifestyle, environment, and behavioral change play a central role in neurodegenerative disease and how advances in biomarkers, prognostics, and AI-driven diagnostics are transforming how clinicians understand and manage conditions like multiple sclerosis, Alzheimer’s disease, and Parkinson’s. Dr. Sharlin explains how tools such as blood-based biomarkers, disease activity scores, and predictive testing can help tailor therapies to the individual rather than relying on trial-and-error prescribing.
Brandon and Dr. Sharlin also dive into the realities of running clinical trials in a crowded therapeutic landscape, the challenges of patient recruitment when effective treatments already exist, and why sponsors must rethink timelines, communication, and study design.
What You'll Learn:
- Why most neurodegenerative diseases are driven by lifestyle and environmental factors - not just genetics
- How restoring biological homeostasis can lead to symptom improvement and potential disease reversal
- The difference between diagnostic, prognostic, and predictive biomarkers and why all three matter
- How precision medicine is changing treatment selection in multiple sclerosis and beyond
- Why behavioral change is foundational to functional and integrative neurology
- The role of emerging technologies like neuromodulation, photobiomodulation, sound, and electromagnetic therapies
- What sponsors often underestimate when designing and launching clinical trials
- Why patient recruitment is becoming harder in MS despite therapeutic advances
- How AI and biomarker-driven tools can accelerate drug development and trial execution
- Dr. Sharlin’s vision for the next 10 years of neurological care and research
About the Guest:
Dr. Ken Sharlin is a board-certified neurologist, clinical researcher, and leader in neurological disease reversal. With over 25 years of experience, his peer-reviewed research shows that cognitive decline and early Alzheimer’s disease can be improved and in some cases reversed through personalized, systems-based care.
He integrates conventional neurology, precision medicine, functional medicine, and regenerative therapies to treat conditions including Alzheimer’s, multiple sclerosis, Parkinson’s disease, ALS, epilepsy, and chronic migraine. Dr. Sharlin is the founder of the Sharlin Health Neuroscience Research Center, where he leads Phase II–IV clinical trials for next-generation neurotherapeutics, and the creator of the Brain Tune Up! Protocol.
His work focuses on improving brain health, resilience, and quality of life by addressing neurological disease at its root causes.
Power to the Patients is handcrafted by our friends over at: fame.so